All the hoopla surrounding the biotech stock, Dendreon Corp. (DNDN), this year is well deserved. After all, the market potential for its prostate cancer treatment, Provenge, is significant. This year, 190,000 new cases of prostate cancer are expected, with 27,000 deaths from the disease. That makes it the most common non-skin cancer in the United States and the third most common cancer worldwide. But Provenge takes a novel approach to treatment. The drug is the first active … [visit site to read more]  
 |
No comments:
Post a Comment